JMJD6 and non-small cell lung carcinoma: Through human NSCLC tissue arrays, CUT&Tag sequencing, bulk RNA-sequencing, single-cell RNA-sequencing, and a series of in vitro and in vivo experiments, we aim to identify the key downstream transcriptional targets, such as EHF, through which JMJD6 exerts its effects, and to evaluate the radiosensitizing potential of genetic inhibition of JMJD6, providing a rationale for a novel combinatorial therapeutic strategy to overcome treatment failure in post-RT NSCLC patients.